hts

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening;

TargetMol created the L4020 NO-PAINS Compound Library that applied the PAINS filter, remaining 9384 small molecules that are suitable for new drug development, signaling pathway research, drug repurposing and other research.

A unique collection of 4655 pure natural products and their derivatives with known biological activity for drug discovery, pharmacological study, stem cell differentiation, fingerprint study and quality research, and can be used for high throughput screen

A unique collection of 4080 compounds for high-throughput screening and high-content screening,

A unique collection of 2880 approved drugs for high throughput screening (HTS) and high content screening (HCS);

3400 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

Well-chosen 1360 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 9332 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2680 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3230 anticancer drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 653 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 540 gut microbial metabolites which can be used for HTS and HCS;

A unique collection of 2154 compounds related to neurodegenerative diseases can be used for HTS or HCS;

A unique collection of 3550 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A collection of 18720 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of 1855 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3163 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1440 hepatotoxicity causing compounds, a powerful tool for drug toxicity study, can be used for HTS and HCS screening;

Diversity: Selected from 1,600,000 drug-like compounds, 10000compounds representing 5000 scaffolds selected from a large drug-like chemical source;

A unique collection of 750 CNS-Penetrant compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 4221 natural products for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 800 natural polyphenolic compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 945 saccharides and glycosides compounds can be used for HTS and HCS;